Clinical Safety

FDA vs. EMA: Which Agency Balances Innovation and Safety Better?
Management & Regulatory FDA vs. EMA: Which Agency Balances Innovation and Safety Better?

Innovation thrives at the intersection of regulatory flexibility and robust oversight, especially within the dynamic field of first-in-class drugs. Today, we delve into this critical topic with Ivan Kairatov, a seasoned biopharma expert with extensive experience in research and development. With a

Can CAR T-Cell Therapy Transform Treatment for Systemic Sclerosis?
Research & Development Can CAR T-Cell Therapy Transform Treatment for Systemic Sclerosis?

The medical landscape has been witnessing a groundbreaking shift with the advent of novel therapies aimed at tackling some of the most challenging conditions. One such development is the Phase 1/2 clinical trial of Cabaletta Bio's CAR T-cell therapy, rese-cel (resecabtagene autoleucel),

Can Combination Immunotherapy Transform GI Cancer Treatment?
Research & Development Can Combination Immunotherapy Transform GI Cancer Treatment?

The world of personalized cancer treatment has seen groundbreaking advancements with the introduction of combination immunotherapy, particularly in the realm of metastatic gastrointestinal (GI) cancers. Researchers at the National Cancer Institute (NCI) have developed a transformative approach that

Impact of Peter Marks' Departure on Cell and Gene Therapy at FDA
Research & Development Impact of Peter Marks' Departure on Cell and Gene Therapy at FDA

The recent resignation of Peter Marks as the head of the FDA's Center for Biologics Evaluation and Research (CBER) marks a significant moment for the cell and gene therapy industry. His departure has sparked widespread discussion about the future direction of the regulatory landscape and its

How Will AI and ML Transform Patient Care Through NJII and Cognome Partnership?
Tech & Innovation How Will AI and ML Transform Patient Care Through NJII and Cognome Partnership?

In an era where technology is constantly evolving the healthcare landscape, the recent partnership between the New Jersey Innovation Institute (NJII) and Cognome holds significant promise. This alliance is poised to make substantial strides in improving patient care through the integration of

Can Eye Drops Prevent Vision Loss in Retinitis Pigmentosa Patients?
Research & Development Can Eye Drops Prevent Vision Loss in Retinitis Pigmentosa Patients?

Retinitis pigmentosa, an inherited retinal disease, is characterized by progressive vision loss over time, ultimately leading to severe visual impairment. The disease affects the retinal photoreceptor cells, where the degeneration results in the gradual loss of night vision, peripheral vision, and

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later